The renaissance of metformin in endocrine clinical practice

References

• Nathan D M, Buse J B, Davidson M B, Heine R J, Holman R R, Sherwin R, Zinman B. Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721
   PubMed Web of Science ®Google Scholar
• Cryer P E, Comment on, Nathan D M, Buse J B, Davidson M B, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721, 222
   PubMed Web of Science ®Google Scholar
• Schultes B, Comment on, Nathan D M, Buse J B, Davidson M B, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721, 225
   PubMed Web of Science ®Google Scholar
• Porta M, Trento M, Comment on, Nathan D M, Buse J B, Davidson M B, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721, 227
   PubMed Web of Science ®Google Scholar
• Takamura T, Shimizu A, Ando H, Kaneko S, Comment on, Nathan D M, Buse J B, Davidson M B, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711–1721, 229
   PubMed Web of Science ®Google Scholar
• Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2008. Diabetologia Praktyczna 2008; 9(Suppl A)
   Google Scholar
• Knowler W C, Barrett-Connor E, Fowler S E, Hamman R F, Lachin J M, Walker E A, Nathan D M. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention and metformin. N Engl J Med 2002; 346: 393–403
   PubMed Web of Science ®Google Scholar
• Nathan D M, Davidson M B, De Fronzo R A, Heine R J, Henry R R, Pratley R, Zinman B. American Diabetes Association. Impaired fasting Glucose and impaired glucose tolerance. Diabetes Care 2007; 30: 753–759
   PubMed Web of Science ®Google Scholar
• Lord J M, Flight I HK, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951
   PubMed Web of Science ®Google Scholar
• Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX. Trends Endocrinol Metab 2003; 14: 365–370
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence – Fertility-Assessment and Treatment for People with Fertility Problems – Clinical Practice Algorithm February 2004. Available at: www.nice.org.uk
   Google Scholar
• Cabin R H, Futerweit W, Reaven G M, Jellinger P S, Handelsman Y, Redmond G P, Thcatcher S S. American Association of clinical endocrinology position statement on metabolic and cardiovascular consequences of PCOS. Endocr Pract 2005; 11: 125–135
   Google Scholar
• Legro R S, Myers E R, Barnhart H X, Carson S A, Diamond M P, Carr B R, Schlaff W D, Coutifaris C, McGovern P G, Cataldo N A, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril 2006; 86(4)914–933, Epub 2006 Sep 11
   PubMed Web of Science ®Google Scholar
• Jakubowicz D J, Seppälä M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R, Nestler J E. Insulin reduction with Metformin increases luteal phase serum glycodelin and insulin-like growth factor binding protein 1 concentration and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1126–1133
   PubMed Web of Science ®Google Scholar
• Khattab S, Mohsen I A, Foutouh I A, Ramadan A, Moaz M, Al-Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 680–684
   PubMed Web of Science ®Google Scholar
• Milewicz A, Jędrzejuk D. Clinical aspects of obesity in the gynecological endocrinologicaly practice. Maturitas 2007; 56: 113–121
   PubMed Web of Science ®Google Scholar
• Gilbert C, Valais M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86: 658–663
   PubMed Web of Science ®Google Scholar
• Briggs G G, Freeman R K, Yaff S J. Drugs in Pregnancy and Lactation. Lippincott, Williams and Wilkins, Philadelphia, PA 2002
   Google Scholar
• Ibáñez L, Valls C, Ong K, Dunger D B, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 2006; 91: 2068–2073
   PubMed Web of Science ®Google Scholar
• Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160: 241–246
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346–403
   Web of Science ®Google Scholar
• Pokrywka G S. Diagnosis and treatment of metabolic syndrome on menopausal women. Menopause Manage 2007; 16: 16–26
   Google Scholar